Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Shionogi’s Novel Antibiotic Fetroja Gets Fast-Track Listing for Dec. 20
December 14, 2023
- Koshiro Slapped with 40-Day Biz Suspension over GMP Violations
December 14, 2023
- MHLW Evaluation Panel Won’t Discuss Rx-to-OTC Switches for Injectable Drugs
December 13, 2023
- Sales of Patented Drugs to Be Excluded from “Innovation Box” Tax Relief Scheme
December 13, 2023
- Leqembi OK’ed for Listing on Dec. 20; Peak Sales Put at 98.6 Billion Yen
December 13, 2023
- Panel Snubs Outline of Guidelines for Supply Info Reporting, Production Requests Due to Lack of Explanations
December 12, 2023
- Japan Reform Minister Calls for Roadmap to Eliminate “Switch Lags” in 3 Years
December 12, 2023
- Ultragenyx’s Evinacumab, Alexion’s Danicopan in Line for Japan Approval
December 11, 2023
- Japan Panel OKs Basic Plan for Elective Care Scheme for LLPs; 900 APIs Targeted
December 11, 2023
- Will R&D Tax Credit Be Scaled Back with “Innovation Box” Rollout? Political Settlement Likely
December 8, 2023
- Sawai’s Revlimid Generic, BMS’ AG Now Available; Trerief AG Launch Set for Feb. 20
December 8, 2023
- Japan Diet Enacts Bill to Lift Ban on Cannabis-Derived Drugs
December 8, 2023
- First Generics for 5 APIs to Join NHI Price List; No Entries for Januvia, Zytiga
December 7, 2023
- JPWA Calls for Permanent Mechanism to Shore Up Drug Prices
December 7, 2023
- Pharma Industry Backs MHLW Proposal to Scrap PMP Indicators: Chuikyo Hearing
December 7, 2023
- CEFP Discusses Social Security Reform Timeline, No Surprises for Pharma Measures
December 6, 2023
- Authorized Generics Cannot be Regulated Now but Must Be Watched Closely: MHLW Panel Members
December 5, 2023
- 500 Billion Yen-Plus Annual Savings Expected from Generic Switches: Reiwa Rincho
December 5, 2023
- Japan Eyes Stronger OTC Sales Restrictions Due to Drug Abuse
December 4, 2023
- Reliance on Drug Price Cuts to Pool Financial Resources Must End: LDP Lawmakers
December 4, 2023
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…